NR3C2 and hydrops fetalis: Alternatively, in our sample of patients with WCHF, HF therapies that modify the disease (e.g. ACEIs, ARBs, beta‐blockers, and mineralocorticoid/aldosterone receptor antagonists) were underutilized.3